Vera Therapeutics Announces TRUTAKNA Met Endpoints in ORIGIN 3 Trial

What Happened
On September 15, 2026, Vera Therapeutics, Inc. (Item 7.01 Regulation FD Disclosure) announced that TRUTAKNA™ (atacicept‑vymj) met all prespecified endpoints of the final efficacy analysis of the Phase ORIGIN 3 trial in adults with primary IgA nephropathy (IgAN) who are at risk for disease progression. The company furnished a press release and an updated corporate presentation reflecting the final efficacy analysis as Exhibits 99.1 and 99.2 to the Form 8‑K.

Key Details

• Announcement date: September 15, 2026 (Filed on Form 8‑K, Item 7.01).
• Drug: TRUTAKNA™ (atacicept‑vymj).
• Trial: ORIGIN 3 — final efficacy analysis in adults with primary IgA nephropathy at risk for progression.
• Company disclosures: Press release (Exhibit 99.1) and updated corporate presentation including the data and a “Forward‑Looking Statements” slide (Exhibit 99.2).

Why It Matters
Meeting all prespecified endpoints in a final efficacy analysis is a major clinical milestone for a development‑stage drug. For investors, this is material information about Vera Therapeutics’ clinical progress in IgAN and has been formally disclosed via SEC Regulation FD and an updated corporate presentation. The filing itself does not announce regulatory approval, commercial terms, or financial results; it provides the company’s clinical outcome and related materials for investors to review.